These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34447749)

  • 1. PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab.
    Liu Q; Xin C; Chen Y; Yang J; Chen Y; Zhang W; Ye L
    Front Cell Dev Biol; 2021; 9():696558. PubMed ID: 34447749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of PUM1 by miR-218-5p promotes colorectal tumor-initiating cell properties and tumorigenesis by regulating the PI3K/AKT axis.
    Liu QZ; Yu HR; Wang LP; Zhou MJ; Chen Z; Zhou DH; Chen JY; Zhang N; Huang ZX; Xie YX; Gu FF; Li K; Tu XH
    J Gastrointest Oncol; 2023 Feb; 14(1):233-244. PubMed ID: 36915463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of genes responsible for cetuximab sensitization in colorectal cancer cells using CRISPR-Cas9.
    Hu TT; Yang JW; Yan Y; Chen YY; Xue HB; Xiang YQ; Ye LC
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33048115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA binding protein PUM1 promotes colon cancer cell proliferation and migration.
    Gor R; Sampath SS; Lazer LM; Ramalingam S
    Int J Biol Macromol; 2021 Mar; 174():549-561. PubMed ID: 33508364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel long noncoding RNA CRART16 confers cetuximab resistance in colorectal cancer cells by enhancing ERBB3 expression via miR-371a-5p.
    Zhang X; Wen L; Chen S; Zhang J; Ma Y; Hu J; Yue T; Wang J; Zhu J; Bu D; Wang X
    Cancer Cell Int; 2020; 20():68. PubMed ID: 32158358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
    Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-411-5p acts as a tumor suppressor in non-small cell lung cancer through targeting PUM1.
    Xia LH; Yan QH; Sun QD; Gao YP
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5546-5553. PubMed ID: 30229827
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Wang Y; Sun L; Wang L; Yu H; Yu X; Zou Y
    Biochem Cell Biol; 2021 Dec; 99(6):735-740. PubMed ID: 34734756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
    Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
    Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1.
    Dai H; Jiang Y; Luo Y; Bie P; Chen Z
    Phytomedicine; 2019 Sep; 62():152953. PubMed ID: 31128486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab.
    Kumar SS; Tomita Y; Wrin J; Bruhn M; Swalling A; Mohammed M; Price TJ; Hardingham JE
    Clin Transl Oncol; 2017 Jun; 19(6):718-726. PubMed ID: 28005260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morin inhibits colon cancer stem cells by inhibiting PUM1 expression in vitro.
    Gor R; Saha L; Agarwal S; Karri U; Sohani A; Madhavan T; Pachaiappan R; Ramalingam S
    Med Oncol; 2022 Oct; 39(12):251. PubMed ID: 36224472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
    Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
    Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PUMILIO proteins promote colorectal cancer growth via suppressing p21.
    Gong Y; Liu Z; Yuan Y; Yang Z; Zhang J; Lu Q; Wang W; Fang C; Lin H; Liu S
    Nat Commun; 2022 Mar; 13(1):1627. PubMed ID: 35338151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inducing Cytotoxicity in Colon Cancer Cells and Suppressing Cancer Stem Cells by Dolasetron and Ketoprofen through Inhibition of RNA Binding Protein PUM1.
    Gor R; Gharib A; Dharshini Balaji P; Madhavan T; Ramalingam S
    Toxics; 2023 Aug; 11(8):. PubMed ID: 37624174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
    Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP
    World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib.
    De Pauw I; Lardon F; Van den Bossche J; Baysal H; Pauwels P; Peeters M; Vermorken JB; Wouters A
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30650638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.